SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: 2024-04-11 | Period of Report: 2024-04-08 SEC Accession No. 0000898432-24-000311

(HTML Version on secdatabase.com)

FILER

Bellevue Life Sciences Acquisition Corp.

CIK:1840425| IRS No.: 845052822 | State of Incorp.:DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-41390 | Film No.: 24838766 SIC: 3841 Surgical & medical instruments & apparatus Mailing Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004 Business Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004 425-635-7700

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 8, 2024

| | FE SCIENCES ACQUISITION (| |
|--|------------------------------------|---------------------|
| (Exact Name | of Registrant as Specified in Char | ter) |
| Delaware | 001-41390 | 84-5052822 |
| (State or Other Jurisdiction | (Commission | (IRS Employer |
| of Incorporation) | File Number) | Identification No.) |
| 10900 NE 4th Street, Suite 2300, Bellevue, Washing | on | 98004 |
| (Address of Principal Executive Offices) | | (Zip Code) |
| Registrant's telephone number, including area code | (| 425) 635-7700 |
| | | |
| | Not Applicable | |

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

| | Trading | Name of each exchange on |
|--|-----------|-----------------------------|
| Title of each class | Symbol(s) | which registered |
| Units, each consisting of one share of | BLACU | The Nasdaq Stock Market LLC |
| common stock, one redeemable warrant | | - |
| and one right | | |
| Common stock, par value \$0.0001 per | BLAC | The Nasdaq Stock Market LLC |
| share | | - |
| Redeemable warrants, exercisable for | BLACW | The Nasdaq Stock Market LLC |
| shares of common stock at an exercise | | - |
| price of \$11.50 per share | | |
| Right to receive one-tenth $(1/10)$ of one | BLACR | The Nasdaq Stock Market LLC |
| share of common stock | | |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \blacksquare

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 1.01. Entry into a Material Definitive Agreement.

The information provided in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On April 8, 2024, Bellevue Life Sciences Acquisition Corp. (the "*Company*") issued an unsecured promissory note (the "*Promissory Note*") in the principal amount of \$1,200,000 to Bellevue Global Life Sciences Investors, LLC ("*BGLSI*"), the sponsor of the Company.

The Promissory Note is not interest bearing and is payable in full on the earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination (the "*Maturity Date*"). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company's Amended and Restated Certificate of Incorporation (as subject to extension), BGLSI agrees to forgive the principal balance of the Promissory Note, except to the extent of any funds remaining outside of the Company's trust account, if any. The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action.

The foregoing description of the Promissory Note is qualified in its entirety by reference to the full text of the Promissory Note, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 8.01. Other Events.

On April 9, 2024, \$60,000 was deposited in the trust account in connection with the extension of the date by which the Company must consummate a business combination from April 15, 2024 to May 14, 2024.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit No. | Description |
|-------------|--|
| <u>10.1</u> | Promissory Note, dated April 8, 2024, issued by Bellevue Life Sciences Acquisition Corp. to Bellevue Global Life |
| | Sciences Investors, LLC |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 11, 2024

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer

PROMISSORY NOTE

Principal Amount: \$1,200,000

Dated April 8, 2024

Bellevue Life Sciences Acquisition Corp., a Delaware corporation and blank check company (the "**Maker**"), promises to pay to the order of Bellevue Global Life Sciences Investors LLC or its registered assigns or successors in interest (the "**Payee**"), the principal sum of one million, two hundred thousand dollars (\$1,200,000) in lawful money of the United States of America, on the terms and conditions described below. All payments on this note ("**Note**") shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

1. **Principal.** The principal balance of this Note shall be payable by the Maker on the earlier of: (i) December 31, 2024 or (ii) the date on which Maker consummates an initial business combination (the "Maturity Date"). The principal balance may be prepaid at any time. Under no circumstances shall any individual, including but not limited to any manager, member, officer, director, employee or stockholder of the Maker, be obligated personally for any obligations or liabilities of the Maker hereunder.

2. Interest. No interest shall accrue on the unpaid principal balance of this Note.

3. Representations and Warranties. Maker represents and warrants to Payee on the date hereof as follows:

(a) Existence. Maker is a corporation duly incorporated, validly existing and in good standing under the laws of the state of Delaware.

(b) <u>Power and Authority</u>. Maker has the power and authority, and the legal right, to execute and deliver this Note and to perform its obligations hereunder.

(c) <u>Authorization; Execution and Delivery</u>. The execution and delivery of this Note by Maker and the performance of its obligations hereunder have been duly authorized by all necessary corporate action in accordance with all applicable laws. The Maker has duly executed and delivered this Note.

(d) <u>No Approvals</u>. No consent or authorization of, filing with, notice to or other act by, or in respect of, any governmental authority is required in order for Maker to execute, deliver, or perform any of its obligations under this Note.

(e) <u>No Violations</u>. The execution and delivery of this Note and the consummation by the Maker of the transactions contemplated hereby do not and will not (a) violate any provision of Maker's organizational documents; (b) violate any law applicable to the Maker or by which any of its properties or assets may be bound; or (c) constitute a default under any material agreement or contract by which Maker may be bound.

(f) <u>Enforceability</u>. The Note is a valid, legal and binding obligation of Maker, enforceable against Maker in accordance with its terms except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors' rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law).

4. Events of Default. Each of the following shall constitute an event of default ("Event of Default"):

(a) <u>Failure to Make Required Payments</u>. Failure by Maker to pay the outstanding balance due pursuant to this Note within five (5) business days of the date specified in Section 1 above.

(b) <u>Voluntary Bankruptcy, Etc</u>. The commencement by Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the taking of corporate action by Maker in furtherance of any of the foregoing.

(c) <u>Involuntary Bankruptcy, Etc</u>. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days.

5. Remedies.

(a) Upon the occurrence of an Event of Default specified in Section 4(a) hereof, Payee may, by written notice to Maker, declare this Note to be due immediately and payable, whereupon the outstanding balance of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.

(b) Upon the occurrence of an Event of Default specified in Sections 4(b) and 4(c), the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall automatically and immediately become due and payable, in all cases without any action on the part of Payee.

6. Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, or any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

7. Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to Maker or affecting Maker's liability hereunder.

8. Notices. All notices, statements or other documents which are required or contemplated by this Agreement shall be made in writing and delivered (i) personally or sent by first class registered or certified mail, or overnight courier service, to the address most recently provided to such party or such other address as may be designated in writing by such party, (ii) by facsimile to the number most recently provided to such party or such other fax number as may be designated in writing by such party or (iii) by electronic mail, to the electronic mail address most recently provided to such party or such other such party or such other electronic mail

address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

9. Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

10. Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

11. Trust Waiver. Notwithstanding anything herein to the contrary, the Payee hereby waives any and all right, title, interest or claim of any kind ("Claim") in or to any distribution of or from the trust account established in which the proceeds of the initial public offering (the "IPO") conducted by the Maker (including the deferred underwriters discounts and commissions) and the proceeds of the sale of the units issued in a private placement that occurred in connection with the IPO are to be deposited (the "Trust Account"), as described in greater detail in the registration statement and prospectus filed with the Securities and Exchange Commission in connection with the IPO (the "Registration Statement"), and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever; provided, however, the Payee shall not waive any Claim it may have if the Maker fails to repay the outstanding balance due in connection with this Note pursuant to Section 4(a) hereof. In addition, Payee hereby agrees that the principal balance of this Note will be forgiven if the Maker is unable to consummate an initial business combination on or prior to the time provided in Maker's Amended and Restated Certificate of Incorporation (as subject to extension), except to the extent of any funds held by Maker outside of the Trust Account.

12. Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker and the Payee.

13. Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent shall be void.

[Signature Page Follows]

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

By: <u>/s/ Kuk Hyoun Hwang</u>

Name: Kuk Hyoun Hwang Title: Chief Executive Officer Email: [**]

Payee hereby acknowledges and agrees to the foregoing as of the date first written above.

ACKNOWLEDGED AND ACCEPTED

BELLEVUE GLOBAL LIFE SCIENCES INVESTORS LLC

By: Bellevue Capital Management LLC, Its Manager

By: <u>/s/ Kuk Hyoun Hwang</u> Name: Kuk Hyoun Hwang Title: Chief Executive Officer Email: [**]

Document and Entity Information

| Entity Listings [Line Items] | |
|--|---|
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Apr. 08, 2024 |
| Entity File Number | 001-41390 |
| Entity Registrant Name | BELLEVUE LIFE SCIENCES ACQUISITION CORP. |
| Entity Central Index Key | 0001840425 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 84-5052822 |
| Entity Address, Address Line One | 10900 NE 4th Street |
| Entity Address, Address Line Two | Suite 2300 |
| Entity Address, City or Town | Bellevue |
| Entity Address, State or Province | WA |
| Entity Address, Postal Zip Code | 98004 |
| City Area Code | 425 |
| Local Phone Number | 635-7700 |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Units, each consisting of one share of common stock, one | |
| redeemable warrant and one right [Member] | |
| Entity Listings [Line Items] | |
| Title of 12(b) Security | Units, each consisting of one share of common stock, one redeemable warrant and one right |
| Trading Symbol | BLACU |
| Security Exchange Name | NASDAQ |
| Common stock, par value \$0.0001 per share [Member] | |
| Entity Listings [Line Items] | |
| Title of 12(b) Security | Common stock, par value \$0.0001 per share |
| Trading Symbol | BLAC |
| Security Exchange Name | NASDAQ |
| Redeemable warrants, exercisable for shares of common | |
| stock at an exercise price of \$11.50 per share [Member] | |
| Entity Listings [Line Items] | |
| Title of 12(b) Security | Redeemable warrants, exercisable for shares of |

Trading Symbol

share

BLACW

common stock at an exercise price of \$11.50 per

Apr. 08, 2024

Security Exchange Name Right to receive one-tenth (1/10) of one share of common stock [Member] Entity Listings [Line Items] Title of 12(b) Security

<u>Trading Symbol</u> <u>Security Exchange Name</u> Right to receive one-tenth (1/10) of one share of common stock BLACR NASDAQ

NASDAQ



} }, "auth_ref": [] "lang": { "en-us": { "role": { "label": "document coument Fiscal Period Focus", ion"- "Fiscal period values are FY, Ql, Q2, and Q3. 1st, 2nd and 3rd q }, "auth_ref": [] "http://--'lag': { "encust: { "cole": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal ye }, "auth_ref": [] "auth_ref": [] "auth_ref": [] "authype": "dataItempys". "naurit" "Mitry/Jablies_gov/dat/2023", "lociname": "DocumentPeriodEndDate", "presentation": ["try://wilewice.com/role/DocumentAndE "lang": ["author:" "try: "abdot": "Tocument Period End Date", "documentAtion": "For the EDGAR submis] ed: for the EDGAR sub)), "auth_ref": [] i.ang": {
 "an-us": {
 "an-us": {
 "anbel": "Document Type",
 "documentation": "The type ath_ref": [] }, "ele. EntityAddressAddressLinel": {
 "whiTuype": "normalizedStringIteenType",
 "nour1:" "http://brlace.gov/del/2023",
 "localname": "EntityAddressAddressLinel",
 "presentation": [
 "http://bellevuecm.com/role/DocumentAndEn",
 "http://bellevuecm "http://... jiang": ("encer: ("ile:", "Enciry Address, Address line One", "ile: "Enciry Address Address Line Acto, Building Name, Stre "documentation", "Address line 1 such as Atto, Building Name, Stre), "auth_ref": [])." "ing": ["ecuar: ["Elar: " "folar: " documentation": "Address line 2 such as Street or Suite number" }, "auth_ref": [] "such_ref":[1] "sign_relyadorselddreamilten"":["shallinger."normalisedtrigitend"ges", "samit": http://dxi.sec.go/dk//202", "locilames": "BritiyAddreamAdfessiina", "presentie", "samit", "tage:", "samit", "tage:", "samit", "Entry Address, Address line 3 such as an Office Park"] "documentation": "Address line 3 such as an Office Park"] "auth_ref": [] "http:// "lang": ("schus": ("scla": ("tabel": "Entity Address, City or Town", "tabel": "Entity Address, City or Town", "documentation": "Name of the City or Town",)), "auth_ref": [] "autr_pur: 11
"doi: AntityAddressCountry": [
"shitsype': "countryCodeItemType",
"hottp://ballevue.cov/de/ZO23",
"locainame": "EntityAddressCountry",
"presentation": [
"http://bellevuecn.com/role/DocumentAndEntityTil]
"http://bellevuecn.com/role/DocumentAndEntityTil] "Thty... j.img": ("en-ue"; ("en-ue"; ("documentation"; "ISO 3166-1 alpha-2 country code." .)), "auth_ref": [] }, "eieEntityAddressPostalZipCode": {
 "xhTitype": "normalizedStringItesmType",
 "nauri: "http://bblace.ogo/dd/2023",
 "localname": "EntityAddressPostalZipCode"
 "presentation": [
 "http://bellevuecm.com/role/DocumentAndE "tang": ["tang": ["riang": ["riang": formula": ["tang": formula": "Code for the postal or zip code",)), "auth_ref": [] "Bity. Jiang": ("erus": ("sile": "Enlis": "Saity Address, State or Province", "documentation": "Hame of the state or province." "auth_ref": [] auti_set: ii /auti_set.restricterstlndoxKey": { "xhrtypps": "centralIndoxKeyTeenTyps", "nauri!" "http://khl.ac.gov/dsi/2023", "localname": "EntityCentralIndexKey", "presentation": ["http://bellevuecm.com/role/DocumentAnd]; l." ... 'indot's 'indot's 'indot's 'indot's Key', 'indot's 'Entry Central Index Key', 'indot's 'Builty Central Index Key', 'indot's 'Builty Central Index Key', 'indot's 'Builty Central Index Key',

> Copyright © 2024 years and contrasts core. All Rights Reserved. Please Consider the Environment Before Printing This Document

}, "auth_ref": ["r1"), dai_EntityEmergingGrowthCompany": { "kbltype": "booleanItenType", "naur!", "http://bol.aec.gov/dd/2023", "loolinae": "BhltyEmergingGrowthCompany", "http://bellevuecn.com/role/DocumentAndEmily. "http://www.j lang":("en-ur";("en-ur";("lang":"Entity Emerging Growth Company", "documentation"; "Indicate if registrant meets the emerging growth company documentation"; }, "auth_ref": ["r1"

}, "ede EntityExTransitionPeriod": { "xbritype": "booleanItemType", "nauri:" "http://xbl.ac.gov/ds/2023", "localname": EntityExTransitionPeriod", "presentation": ["http://bellevuecm.com/role/DocumentAndI "http://bellevuecm.com/role/DocumentAndI

"mtpp... lang": ("acuar: ("tole": { "label": fentity Ex Transition Period", "documentation": "Indicate if an emerging

)), "auth_ref": ["r7" }, "edi EntityFileNumber": { "xhTitype": "fileNumberTemType", "nour1:" "http://xhTisec.gov/ddi/2023", "localname": "EntityFileNumber", "presentation": ["http://bellevuecm.com/role/DocumentAndE "http://bellevuecm.com/role/DocumentAndE

"lang": ["lang": ["en-us": ["clola": ["label": "Entity File Number", "documentation": "Commission file

"auth_ref": []

image: i; ded_EntityIncorporationStateCountryCode": { "shiType", "adapartistateCountryCode"; { "shiType", "adapartistateCountryCode"," "noalname": "EntityIncorporationStateCountryCode", "presentation": ["http://bellevuecn.com/role/DocumentAndEntityInformation"]

"http://www.i iang".i "we-wa".i "siat".i Takity Incomposation, State of Country Code", "siat".i Takity Incomposation, State of Country Code", "documentation": "Non-character ECGAR code representing the state or country of in)), "auth_ref": []

"doi_EntlyListingslineTtems": {
 "adoi_EntlyListingslineTtems": {
 "adoi_EntlyIstent_status
 "adoi_EntlyListingslineTtems",
 "localname": "EntlyListingsLineItems",
 "presentation": [
 "http://bellevuecn.com/role/DocumentAnd
 1.

"http:// "ang": ["sole": ["tole": "Entity Listings [Line Items]", "documentation": "Line items represent fin

ers defined in one or many ax

fied in its charter, which is required by forms filed with the SEC.

mber may contain 1-8 digits,

"auth_ref": []

These ... Jiang I ["enue": ["sole": "Entity Listings [Table]", "label": "Entity Listings [Table]", "documentation": "Container for exchange listing info. .

}, "auth_ref": []

) "auth_ref": ["r1"

] Jau Deriyflad deniffoxiosHashart": [daal Diygat. SageSystellianByper "massi", "they'shalaes.gov/al/023", "boolmans": "EntiyfationiffoxiosHashart", "presentation", "tang": ["tan er Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

)), "auth_ref": ["r1"

interpret/i

)), "auth ref": []

}, " " del_NOTradingSymbolFlag": { "xbrltype": "treeItemType", "nauri:" http://xbrl.ace.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": ["http://bellevuecm.com/role/DocumentAnd],

"http://..." 11.1403":["encur:["ribe:["ident:" The Trading Symbol Flag", "documentation": "Moolean flag that is true only for a sec

th_ref": []

}, Gei PreCommencementIssuerTenderOffer": { "kbltype": "booleanItemType", "neurt": "http://kblisec.gov/dai/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://bellevuecn.com/role/DocumentAndEntityInni "htt

le "inang": ("an-us": ("inalu": "Fre-commencement Issuer Tender Offer", "inalu": "Fre-commencement Issuer Tender Offer",

}, "auth_ref": ["r3"

"dei_PreCommencementTenderOffer": { "xbrltype": "booleanItenType",

nt to Rule 13e-4(c) under the Ex

"nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": ["http://bellevuecm.com/role/DocumentAndEn]. "Thisp...." "Interview" "ancust" ("ancust") "accust" "Accust The Commencement Tender Offse", "Accust The Commencement Tender Offse", "Accust Tender The Commencement Tender Offse", "Accust Tender Tender Tender Tender Tender Tender Tender Tender "Accust Tender Tender Tender Tender Tender Tender Tender Tender Tender "Accust Tender tions pursuant to Rule 14d-2(b) under the Exc) }, "auth_ref": ["r4" }, blacu BedeemableWarrantsExercisableForSharesOfCommonStockAt "xhrltpyme": "domainLemmType", "nosri": "http://bellewaeen.com/20240408", "localname": RedeemableWarrantsExercisableForSharesOfCommon "presentation": ["http://bellewaeen.com/role/DocumentAndEntityInformation"]. ckAtAnExercisePriceOf1150PerShare], "lang": { "en-us": { "role": { "label": "R rants, exercisable for shares of c on stock at an exercise price of \$11.50 per share [M))), "auth_ref": [] aum_net:11 /aum_net:11 /along RightGosiveOne@facth100fOneShareOfCommonStockMesbe makritype: "domainLearNype", "neuris", "furt//belleveen.com/20204063", "lociname": "RightGaseiveOne@facth1100fOneShareOfCommonSt "presentation":["http://bellevuecn.com/role/DocumentAndEntityInformation"], "http://www.i samag": ["servis": ["side": ["shal": "Night to receive one-tenth (1/10) of one share of common stock [Member]" , "shal": "Night to receive one-tenth (1/10) of one share of common stock [Member]"), "auth_ref": [] "autm_ser: []
dod_Security2Dfills": {
 "hbritypa"."security1illTenType",
 "naurit.""http://hblis.ec.gov/dsi/2023",
 "localname": Security12b7ille",
 "presentation": [
 "http://bellevuecm.com/role/DocumentAndf
], "RETy...]img7: { "eccus"; { "eccus"; { ... "documentation"; "Title of a 12(b) registered security." ... "documentation"; "Title of a 12(b) registered security.")), "auth_ref": ["r0"].est_SecurityExchangeName": {
 "xhlipype": "edgaTxchangeCodsItesType",
 "nant": "http://xhlise.gov/dai/2023",
 "localname": "SecurityExchangeName",
 "presentation": {
 "http://bellevuecn.com/role/DocumentAndEnt
]. "faty.... "isag": ["encur:] "isag": ["isag": [Security Exchange Hams", "isag": [Security Exchange G the Exchange on Which a security is registered.") "auth_ref": ["r2"), di SolicitingMaterial": { "xbrltype": "bocleanitumType", "mauri": "http://xbrl.scc.gov/ds//2023", "localname": "SolicitingMaterial", "presentation": ["http://bellevuecn.com/role/DocumentAndEntityInform]. "TEEP/10 Answerse Taboy": ["Answerse":] ""TEEP": "Boligan ("TEEP": "Boligan flag that is true when the Form 0-% filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Bule 14s-12 under the Exchange Act," "Accumentation": "Boligan flag that is true when the Form 0-% filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Bule 14s-12 under the Exchange Act," "Accumentation": "Boligan flag that is true when the Form 0-% filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Bule 14s-12 under the Exchange Act," } "auth_ref": ["r5") us-gaag_BtatementClassOfStockAkis": { **autitype: *stringItemType*, *sauti: *trip://fash.org/us-gaap/2022*, *sautit: *trip://fash.org/us-gaap/2022*, *researtation; i monitoriockAkis*, *presentation; i monitoriockAkis*, *trip://balkvuscm.com/role/bocumentAndIntityInfor *town*. "l." "lang": ["encus": ["zola": ["label": "Class of Stock [Axis]"))], "auth_ref": [] "aut.rgs: 1; 'aut.rgsdigshebl": { "xblippe", "tradingsymbolItenType", "neart", "tradingsymbol", "localname": Tradingshebl", "presentation": { "http://bellevuecn.com/role/DocumentAndEntityInformation" }; "Refers... jiang": ["en-us" ["en-us" ["en-us" trading hymbol", "documentation"; "Trading symbol of an instrument as listed on an exchange." }, "auth_ref": [] "autr_get*: [] "autr_get*: [] "autr_get*: dominiterpyoe", "autriget*: dominiterpyoe", "autriget*: dominiterpyoe", "autriget*: [] "presentation"; [] "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*, "presentation"; [] "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*, "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*, "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*, "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*, "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*, "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*, "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*, "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*, "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*," "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*," "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAudomaRightMasher*," "thtp://allwace.com/roleAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemableMarrantAutriget/CommonflocKOmeRedeemation* 'thttp://allwacet/CommonflocKOmeRedeemation)), "auth_ref": [] }, " " del WittenCommunications": { "xblitype": "booleanItesType", "nouri": "http://bbliesc.gov/dei/2023", "localname": "WrittenCommunications", "presentation": ["http://bellevuecm.com/role/DocumentAndE]. 8-K filing is inter ded to satisfy the filing obligation nt to Rule 425 under the Securities Act. } }, "auth_ref": ["r6") straft: ("so": ("sola", "http://www.sbrl.org/2003/role/presentationMef", "sola", "http://www.sbrl.org/2003/role/presentationMef", "sola", "sola", "sola", "solater: "sola", "sola", "solater: "solat", "solater: "solat "Diservent for a second 't3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",

> Copylet C 2024 year an Coloran con At Right Reserved. Please Consider the Environment Before Plating This Document

"Heat", "Exchange Act", "House", "2404 "section" =134", "define the section of the section